Virtual Clinical Trials Drive Success Prediction in Heart Failure Drug Development
Mayo Clinic researchers have developed virtual clinical trials using AI and real-world data to predict the success of repurposed drugs for heart failure, speeding up drug development and reducing costs.
Researchers at Mayo Clinic have pioneered an innovative approach to assess the potential effectiveness of existing drugs for treating heart failure by leveraging virtual clinical trials. This method combines sophisticated computer models with real-world patient data, streamlining the drug discovery process by reducing costs, time, and the risk of failure in traditional trials. The team developed an AI-enabled framework that emulates clinical trials by creating comparison groups from electronic health records (EHRs) of nearly 60,000 heart failure patients, allowing for the prediction of a drug's efficacy without conducting actual randomized controlled trials.
The approach incorporates drug-target modeling, which uses artificial intelligence to analyze chemical structures alongside biological data such as protein sequences and genes. This enhances the accuracy of predicting how drugs might perform in real-world settings. The researchers validated their model by retrospectively analyzing 17 drugs that had previously undergone Phase 3 trials in heart failure, successfully predicting the direction of outcomes in 7 beneficial and 10 non-beneficial cases.
This predictive capability enables scientists to identify promising repurposed drugs more efficiently, prioritizing candidates for further testing and potentially accelerating the availability of new treatments. As Dr. Nansu Zong explains, while the current model can determine whether a drug is likely to succeed, the next steps involve quantifying the level of efficacy. The technology has the potential to revolutionize clinical research by making it faster, more affordable, and more accessible, especially through a broader initiative led by Mayo Clinic under Dr. Cui Tao. This initiative explores trial emulation, simulation, and synthetic trials using AI, facilitating a new era of translational science.
Ultimately, these advancements could significantly impact how new therapies are developed and deployed, promising faster access for patients and decreased healthcare costs. Source: https://medicalxpress.com/news/2025-09-virtual-clinical-trials-success-heart.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Safety and Effectiveness of GLP-1 Receptor Agonists for Obesity Treatment in Adults with Mental Illness
New evidence shows GLP-1 receptor agonists are safe and effective in promoting weight loss and improving metabolic health in adults with mental illness, with no increased risk of adverse psychiatric effects. These medications offer promising benefits for addressing obesity in this vulnerable population.
Bridging Gaps in Memory Care for Rural and Indigenous Communities
Innovative research in northern Arizona is addressing overlooked signs of dementia in rural and Indigenous communities by providing early detection, education, and support to promote brain health and prevent progression.
Parental Liver Disease Mortality Significantly Increases Risk of Alcohol-Related Hepatitis in Offspring
A new study reveals that parental death from liver disease more than doubles the risk of alcohol-associated hepatitis in offspring, highlighting the importance of family medical history in prevention and early intervention strategies.